BioMérieux announces that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the Vidas TBI (GFAP, UCH-L1) test.

This serum test enables the evaluation and management of patients with mild traumatic brain injury, including concussion.

The test helps reduce the number of brain scans (CT scans) required for patients with mild traumatic brain injury by predicting the absence of post-traumatic intracranial lesions.

Copyright (c) 2024 CercleFinance.com. All rights reserved.